HOME >> MEDICINE >> NEWS
Patient adherence for successful tuberculosis treatment

Nearly 2 million people die from tuberculosis each year, mainly in the poorest countries. The pathogen, Kochs bacillus, can pass easily by aerial infection from one individual to another. The spread of the disease, favoured by the Aids epidemic and the appearance of multi-resistant strains, has led WHO to make tuberculosis control one of the worlds main health priorities. The existing treatment, which combines several antibiotics prescribed for a period of 6 to 8 months as against 18 months to 2 years still only a few years ago has proved efficient in 95 % of cases. However, this efficacy is called into question by the low adherence of patients to treatment, particularly in the most deprived areas, which are often indeed the worst hit by the disease. In spite of the WHO recommendation to administrate the treatment under the direct supervision of health care personnel who play the role of supporter (DOT : Directly observed therapy), more than 10% of patients stop the treatment before the prescribed period. This defaulting, along with irregularity in taking the medicines, creates increased risk of serious relapse, which opens the way to a rise in transmission events and the emergence of bacteria resistant to the prescribed antibiotics.

Starting from the principle that tuberculosis control must involve the identification of the obstacles to full comprehensive access to treatment, IRD researchers and their partners (1) studied, in Senegal, the different geographical, behavioural and socio-cultural factors that enter into the perception of the treatment and adherence to it.

In these countries, where over 9000 new cases of tuberculosis are diagnosed every year, access to free treatment is provided by the National Tuberculosis Control Programme through government health districts (2). However, nearly 30 % of patients do not follow this treatment correctly and scarcely 60% of people ill from the disease receiving a prescription manage to be cured. W
'"/>

Contact: Marie Guillaume
fichesactu@paris.ird.fr
33-014-803-7607
Institut de Recherche Pour le Dveloppement
27-Mar-2007


Page: 1 2 3

Related medicine news :

1. Patient-centered approach can backfire
2. Patients with soft tissue sarcomas should be treated at high volume centers
3. Patients own platelets may speed up skin wound healing
4. Patients with bleeding strokes less likely to get prevention treatment
5. Patients should be alert for obesity surgery complication
6. Patients with type 1 diabetes dont wake in response to hypoglycemia
7. Cancer Patients Nationwide Can More Easily Navigate Health Care System
8. Patients with PTSD experience less pain sensitivity -- may be related to altered processing
9. Patients requests for antidepressants can influence physician evaluation of depression
10. Patients unaware of risks and purpose of research even after informed consent
11. Patients can report statins adverse effects on new web site

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Patient adherence for successful tuberculosis treatment

(Date:6/19/2013)... (PRWEB) June 19, 2013 Kansas City will host ... Main Street Day . A section of Main Street in ... during the afternoon of the event. The Main Street Corridor ... event, which will help Kansas City join the ranks of dozens ... as a tool to foster community vibrancy and active lifestyles. , ...
(Date:6/19/2013)... In 2011, the value of the ... Generic drugs form the largest sector, accounting for nearly ... industry is a significant contributor to the local economy; ... Approximately 50% of the total domestic chemical industry output ... Galenika and Zdravlje Actavis are key participants in the ...
(Date:6/19/2013)... 19, 2013 Elsevier, a world-leading provider of ... announced today the publication of the National Osteoporosis ... management of osteoporosis in postmenopausal women and older ... Published in 2009 in Maturitas , the ... update is timely with an additional focus on ...
(Date:6/19/2013)... Next Thursday, June 27, 2013, ... organization, and Muzzy Lane Software , a ... the Games for Health community to their interactive ... toward students in grades 4-7 and designed to ... positive choices. The game is part of a ...
(Date:6/19/2013)... Maui'd Forever , Hawaii's premiere ... an effective and cost effective way to provide for ... up with Tom Barefoot’s Tours providing an activity agent ... Hawaii’s activities. , They have just released a new ... lowest prices on their Hawaii activities. , Maui’d ...
Breaking Medicine News(10 mins):Health News:Main Street Corridor Development Corporation and BikeWalkKC Partner to Host Main Street Day and Kansas City’s First Ciclovia 2Health News:Main Street Corridor Development Corporation and BikeWalkKC Partner to Host Main Street Day and Kansas City’s First Ciclovia 3Health News:Serbian Pharmaceutical Market Scrutinized by CUBE in Topical Report Now Available at MarketPublishers.com 2Health News:Adventure Game for Tweens to Promote Healthy Eating will be Unveiled at Games For Health Conference 2Health News:Adventure Game for Tweens to Promote Healthy Eating will be Unveiled at Games For Health Conference 3Health News:Adventure Game for Tweens to Promote Healthy Eating will be Unveiled at Games For Health Conference 4Health News:Adventure Game for Tweens to Promote Healthy Eating will be Unveiled at Games For Health Conference 5Health News:Maui'd Forever Pleased to Offer Price Guarantee on Hawaii Activities 2
(Date:6/19/2013)... NESS ZIONA, Israel , ... today announced that results from a phase I study ... study in advanced Parkinson,s patients, of ND0612, were presented ... Movement Disorders. ND0612 is a proprietary levodopa/carbidopa liquid drug ... (SC) delivery patch that would maintain constant levodopa plasma ...
(Date:6/19/2013)... 19, 2013  This year alone, The Leukemia & ... projects with one goal in mind: Discovering lifesaving therapies ... Training" (TNT), a flagship LLS fundraising campaign and the ... marking its landmark 25 th anniversary. To date, ... in research to discover and deliver breakthrough cancer treatments ...
(Date:6/19/2013)... June 19, 2013   Life Technologies Corporation ... licensing agreement granting Suzhou Ribo Life Sciences (Ribo) ... therapeutics in China using ... proprietary siRNA molecules in combination with Invivofectamine® Rx ... human diseases with high unmet medical need in ...
Breaking Medicine Technology:NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 2NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 3NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 4NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 5NeuroDerm Announces Presentation of Data from Studies Evaluating ND0612, an Investigational Levodopa Continuous Administration Drug, in Healthy Volunteers and in Patients with Advanced Parkinson's Disease 6Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 2Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 3Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 4Celebrating 25 Years and Counting: Leukemia and Lymphoma Society's "Team In Training" Goes the Distance and Beyond for Blood Cancer Patients 5Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 2Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 3Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 4
Cached News: